NCT07577466Not yet recruiting
Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function. Early diagnosis and targeted therapies are essential to improve patient outcomes. This prospective, single-center study aims to longitudinally follow patients with suspected cardiac amyloidosis to characterize disease progression and assess treatment effects. Participants will undergo cardiac magnetic resonance imaging (resting and exercise stress MRI), magnetic resonance spectroscopy, cardiopulmonary exercise testing (spiroergometry) and blood testing at baseline and at 6, 12, and 24 months
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 4 May 2026
- Start date
- 15 Jun 2026
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Heinrich-Heine University, Duesseldorf
- Diseases
- Amyloidosis, Heart failure
- NCT number
- NCT07577466
What you commit to
- Study type: Observational
- Planned participants: 200
- From 15 Jun 2026 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindications to cardiac MRI (e.g., metallic foreign bodies, older-generation pacemakers, severe obesity, claustrophobia)
Age
- Age \< 18 years
Other
- Lack of written informed consent for study participation
- Inability to comply with the study procedures
Who the study is looking for
- Age \> 18 years
- Male and female patients undergoing clinically indicated diagnostic work-up for amyloidosis or with a previously confirmed diagnosis of cardiac amyloidosis prior to initiation of therapy
- Presence of left ventricular wall thickness \> 12 mm on transthoracic echocardiography and at least one "red flag" suggestive of cardiac amyloidosis (according to ESC 2021 criteria) or an otherwise clinically established suspicion of amyloidosis
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Duesseldorf Coordinator of this site? Confirm its status | Düsseldorf | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.